153 related articles for article (PubMed ID: 9107540)
1. Excretion and metabolism of trovafloxacin in humans.
Dalvie DK; Khosla N; Vincent J
Drug Metab Dispos; 1997 Apr; 25(4):423-7. PubMed ID: 9107540
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways.
Dalvie DK; Khosla NB; Navetta KA; Brighty KE
Drug Metab Dispos; 1996 Nov; 24(11):1231-40. PubMed ID: 8937858
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
Vincent J; Teng R; Dalvie DK; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
7. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.
García-Calvo G; Parra A; Aguilar L; Ponte C; Giménez MJ; Carcas A; Kinzig-Schippers M; Soriano F
Antimicrob Agents Chemother; 2001 Jun; 45(6):1876-8. PubMed ID: 11353641
[TBL] [Abstract][Full Text] [Related]
9. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
10. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
Dow J; Piriou F; Wolf E; Dulery BD; Haegele KD
Drug Metab Dispos; 1994; 22(5):738-49. PubMed ID: 7835226
[TBL] [Abstract][Full Text] [Related]
11. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
Balani SK; Xu X; Pratha V; Koss MA; Amin RD; Dufresne C; Miller RR; Arison BH; Doss GA; Chiba M; Freeman A; Holland SD; Schwartz JI; Lasseter KC; Gertz BJ; Isenberg JI; Rogers JD; Lin JH; Baillie TA
Drug Metab Dispos; 1997 Nov; 25(11):1282-7. PubMed ID: 9351905
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
14. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
Vincent J; Venitz J; Teng R; Baris BA; Willavize SA; Polzer RJ; Friedman HL
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():75-80. PubMed ID: 9222074
[TBL] [Abstract][Full Text] [Related]
16. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.
Melnik G; Schwesinger WH; Teng R; Dogolo LC; Vincent J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):424-6. PubMed ID: 9758286
[TBL] [Abstract][Full Text] [Related]
17. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
[TBL] [Abstract][Full Text] [Related]
18. The disposition and metabolism of [14C]fluconazole in humans.
Brammer KW; Coakley AJ; Jezequel SG; Tarbit MH
Drug Metab Dispos; 1991; 19(4):764-7. PubMed ID: 1680653
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
20. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]